Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

The New York Times Company, together with its subsidiaries, provides news and information for readers and viewers across various platforms worldwide. It offers The New York Times (The Times), a daily and Sunday newspaper in the United States, as well as international edition of The Times; and operates the NYTimes.com Website. The company also transmits articles, graphics, and photographs from The Times and other publications to approximately 1,500 newspapers, magazines, and websites; licenses electronic databases to resellers in the business, professional, and library markets; and offers magazine licensing, news digests, book development, and rights and permissions. In addition, it engages in the live events business, which hosts physical and virtual live events to connect audiences with journalists and outside thought leaders; direct-sold website, mobile application, podcast, email, and video advertisements, as well as digital advertising services; operates Wirecutter, a product review and recommendation products; develops mobile applications, including games and cooking products; prints and distributes products for third parties; and offers other products and services. The company was founded in 1851 and is headquartered in New York, New York.

The New York Times Company

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

NEW YORK--(BUSINESS WIRE)--THE NEW YORK TIMES COMPANY (NYSE: NYT) ANNOUNCED TODAY THAT ITS FIRST-QUARTER 2026 FINANCIAL RESULTS ARE AVAILABLE ON THE NEW YORK TIMES COMPANY'S INVESTOR RELATIONS WEBSITE AT INVESTORS.NYTCO.COM. AS PREVIOUSLY ANNOUNCED, THE NEW YORK TIMES COMPANY WILL HOST ITS EARNINGS CONFERENCE CALL TODAY AT 8:00 A.M. E.T. TO DISCUSS THESE RESULTS. A LIVE WEBCAST OF THE EARNINGS CONFERENCE CALL WILL BE AVAILABLE AT INVESTORS.NYTCO.COM. PARTICIPANTS CAN PRE-REGISTER FOR THE TELEPH.

THE NEW YORK TIMES COMPANY REPORTS FIRST-QUARTER 2026 RESULTS

NEW YORK, NEW YORK--(NEWSFILE CORP. - APRIL 29, 2026) - GRIDAI TECHNOLOGIES CORP. (NASDAQ: GRDX), AN AI-POWERED ENERGY ORCHESTRATION PLATFORM OPTIMIZING DISTRIBUTED ENERGY RESOURCES AND NEXT-GENERATION POWER INFRASTRUCTURE, TODAY ANNOUNCED THAT IT WILL BE PARTICIPATING IN THE MARKET MOVERS INVESTOR SUMMIT ON TUESDAY, MAY 5, 2026. THE PRESENTATION WILL TAKE PLACE AT 4:00 PM ET AT THE HISTORIC BANK OF NEW YORK, LOCATED AT 48 WALL STREET, NEW YORK, NY.

GRIDAI TECHNOLOGIES CORP. TO PRESENT AT THE MARKET MOVERS INVESTOR SUMMIT

AIRLINE LAUNCHES FIRST-EVER NONSTOP SERVICE FROMNEWARK/NEW YORKTO SPLIT,CROATIA; SANTIAGO DECOMPOSTELA,SPAIN, AS WELL AS THE INDUSTRY'S ONLY NONSTOP FLIGHTS FROM NEWARK/NEW YORK TO BARI, ITALY; GLASGOW, SCOTLAND UNITED OFFERS CUSTOMERS MORE WAYS TO EXPLORE DESTINATIONS ACROSS THE ATLANTIC THIS SUMMER WITH THE LARGEST SCHEDULE INCLUDING NEARLY 770 WEEKLY TRANSATLANTIC ROUNDTRIPS IN SUMMER 2026 IN 2026, UNITED WILL OFFER FLIGHTS FROM THE U.S. TO36DESTINATIONS IN EUROPEINCLUDINGGREENLAND 14OF WHICH NO OTHER U.S. CARRIER SERVES DESTINATIONS ADDED IN SUMMER 2025 BEGIN AGAIN INCLUDING ULAANBAATAR, FARO, MADEIRA ISLAND, PALERMO, BILBAO AND NUUK CHICAGO, APRIL 28, 2026 /PRNEWSWIRE/ -- THIS WEEK, UNITED AIRLINES WILL KICK OFF ITS SUMMER SCHEDULE WITH SERVICE TO NEW EUROPEAN DESTINATIONS IN CROATIA, ITALY, SCOTLAND AND SPAIN. THE NEW ROUTES BEGIN LAUNCHING APRIL 30  GIVING CUSTOMERS EVEN MORE OPTIONS TO REACH UNIQUE, CULTURALLY RICH DESTINATIONS ACROSS EUROPE.

UNITED AIRLINES LAUNCHES NEW SUMMER FLIGHTS TO SPLIT, BARI, GLASGOW AND SANTIAGO DE COMPOSTELA

NEW YORK, NEW YORK--(NEWSFILE CORP. - APRIL 20, 2026) - KUEHN LAW, PLLC, A SHAREHOLDER LITIGATION LAW FIRM, IS INVESTIGATING WHETHER CERTAIN OFFICERS AND DIRECTORS OF VISTAGEN THERAPEUTICS, INC . (NASDAQ: VTGN ) BREACHED THEIR FIDUCIARY DUTIES TO SHAREHOLDERS.

KUEHN LAW ENCOURAGES INVESTORS OF VISTAGEN THERAPEUTICS, INC. TO CONTACT LAW FIRM

CO-FOUNDER OF MORE THAN 40 BIOTECHNOLOGY COMPANIES, INCLUDING 16 IPOS AND 19 SUCCESSFUL ACQUISITIONS SCIENTIFIC AND MEDICAL TITAN FOCUSED ON DRIVING INNOVATION FOR HUMAN HEALTH WILL ASSIST WITH LISTERIA ONCOLOGY PIPELINE PRIORITIZATION, COMBINATIONS WITH OTHER ONCOLOGY-FOCUSED BIOTECHNOLOGIES AND TADC CANDIDATE SELECTION FOR FURTHER DEVELOPMENT NEW YORK, NEW YORK--(NEWSFILE CORP. - APRIL 13, 2026) - OS THERAPIES, INC. (NYSE AMERICAN: OSTX)("OS THERAPIES" OR "THE COMPANY"), THE WORLD LEADER IN GENE-EDITED, LISTERIA-BASED CANCER IMMUNOTHERAPIES, ANNOUNCED TODAY THAT DR. ROBERT "BOB" S. LANGER, CO-FOUNDER OF MODERNA, WAS APPOINTED TO THE COMPANY'S STRATEGIC ADVISORY BOARD.

OS THERAPIES APPOINTS BIOTECH INDUSTRY LUMINARY ROBERT "BOB" S. LANGER, PHD AS STRATEGIC ADVISOR

SENIOR LEADERSHIP ROLES AT GUARDANT HEALTH, GENENTECH AND PFIZER REGULATORY, CLINICAL AND COMMERCIAL EXPERTISE IN THERAPEUTICS AND BIOMARKERS WILL ASSIST WITH OSTEOSARCOMA REGULATORY ADVICE AND ONCOLOGY PIPELINE PRIORITIZATION NEW YORK, NEW YORK--(NEWSFILE CORP. - APRIL 8, 2026) - OS THERAPIES, INC. (NYSE AMERICAN: OSTX) ("OS THERAPIES" OR "THE COMPANY"), THE WORLD LEADER IN GENE-EDITED, LISTERIA-BASED CANCER IMMUNOTHERAPIES, TODAY ANNOUNCED THAT CRAIG EAGLE, MD, WAS APPOINTED TO THE COMPANY'S NEWLY-FORMED STRATEGIC ADVISORY BOARD. THE COMPANY'S STRATEGIC ADVISORY BOARD IS BEING FORMED TO ASSIST THE COMPANY IN FINE-TUNING ITS OSTEOSARCOMA REGULATORY EXECUTION PLAN AND TO HELP DEVELOP A DETAILED PIPELINE DEVELOPMENT PLAN TO PRIORITIZE THE HIGHEST VALUE OPPORTUNITIES BEYOND OSTEOSARCOMA.

OS THERAPIES APPOINTS CRAIG EAGLE, MD AS STRATEGIC ADVISOR

NEW YORK, NEW YORK--(NEWSFILE CORP. - APRIL 8, 2026) - GRIDSTOR, A DEVELOPER AND OPERATOR OF UTILITY-SCALE BATTERY ENERGY STORAGE SYSTEMS, AND AXPO, A LEADING INTERNATIONAL ENERGY COMPANY HEADQUARTERED IN SWITZERLAND, ANNOUNCED TODAY THE EXECUTION OF AN ENERGY STORAGE AGREEMENT WITH THE HIDDEN LAKES RELIABILITY PROJECT, A 220 MW, 440 MWH BATTERY ENERGY STORAGE SYSTEM LOCATED IN GALVESTON COUNTY, TEXAS, WHICH BEGAN OPERATIONS IN 4Q2025. IN BRIEF: GRIDSTOR AND AXPO HAVE EXECUTED AN ENERGY STORAGE AGREEMENT FOR THE HIDDEN LAKES RELIABILITY PROJECT, A 220 MW, 440 MWH BATTERY STORAGE SYSTEM IN GALVESTON COUNTY, TEXAS.

GRIDSTOR AND AXPO ANNOUNCE BATTERY STORAGE SWAP AGREEMENT

COMPANY EXPECTS APPROXIMATELY $2 MILLION IN NON-DILUTIVE VAT REFUNDS FROM WHOLLY OWNED U.K. SUBSIDIARY IN 2Q-26 COMPANY EXPECTS TO RECEIVE APPROXIMATELY $2 MILLION IN NON-DILUTIVE R&D TAX CREDITS REPAYABLE TO THE COMPANY IN CASH FROM ITS U.K. SUBSIDIARY IN 2H-26 OFFERING NET PROCEEDS, TOGETHER WITH FUNDS EXPECTED TO BE RECEIVED VIA U.K. SUBSIDIARY, EXPECTED TO PROVIDE CASH RUNWAY INTO 2027 COMPANY EXPECTS TO RECEIVE APPROVALS IN THE U.S., U.K. AND EUROPE FOR OST-HER2 IN THE PREVENTION OF DELAY OF RECURRENT, FULLY RESECTED, PULMONARY METASTATIC OSTEOSARCOMA IN THE SECOND HALF OF 2026 NEW YORK, NEW YORK--(NEWSFILE CORP. - APRIL 2, 2026) - OS THERAPIES, INC. (NYSE AMERICAN: OSTX) ("OS THERAPIES" OR "THE COMPANY"), THE WORLD LEADER IN GENE-EDITED, LISTERIA-BASED CANCER IMMUNOTHERAPIES, TODAY ANNOUNCED IT THAT IT HAS COMPLETED A $5.25 MILLION REGISTERED DIRECT OFFERING OF COMMON STOCK (OR PRE-FUNDED WARRANTS IN LIEU THEREOF) AND WARRANTS, WITH PARTICIPATION PRIMARILY FROM HIGH-NET-WORTH INVESTORS WHO HAVE INVESTED IN SEVERAL OF THE COMPANY'S PRIOR FINANCING ROUNDS. EACH INVESTOR WAS ISSUED EITHER SHARES OF COMMON STOCK AT A PURCHASE PRICE OF $1.40 PER SHARE OR, IN LIEU THEREOF, PRE-FUNDED WARRANTS AT A PURCHASE PRICE OF $1.399 PER PRE-FUNDED WARRANT, TOGETHER WITH ONE WARRANT TO PURCHASE ONE SHARE OF COMMON STOCK AT AN EXERCISE PRICE OF $1.40 PER SHARE FOR EACH SHARE OF COMMON STOCK ISSUED OR ISSUABLE UPON EXERCISE OF THE PRE-FUNDED WARRANTS.

OS THERAPIES COMPLETES $5.25M REGISTERED DIRECT OFFERING PRIMARILY WITH PRE-EXISTING HIGH-NET-WORTH INVESTORS

DECEMBER 2025 TYPE C MEETING CONFIRMED IMMUNE BIOMARKERS SUITABILITY TO ESTABLISH SURROGATE CLINICAL EFFICACY THAT COULD SUPPORT BLA UNDER ACCELERATED APPROVAL PATHWAY PRE-SPECIFIED CLINICAL OUTCOMES DATA CORRELATES WITH IMMUNE BIOMARKER SIGNATURE COMPANY POSITIONED TO REVIEW COMPLETED PHASE 2B CLINICAL & BIOMARKER DATA AND CONFIRMATORY PHASE 3 TRIAL PROTOCOL WITH U.S. FDA, EMA AND U.K. MHRA IN 2Q/26 COMPANY EXPECTS TO INITIATE CONFIRMATORY PHASE 3 TRIAL IN AUSTRALIA IN 3Q/26 COMPANY ANTICIPATES RECEIVING A BLA UNDER ACCELERATED APPROVAL PROGRAM IN THE U.S. AND CONDITIONAL MARKETING AUTHORIZATIONS IN EUROPE AND IN THE U.K. IN 2H/26 NEW YORK, NEW YORK--(NEWSFILE CORP. - MARCH 31, 2026) - OS THERAPIES, INC. (NYSE AMERICAN: OSTX) ("OS THERAPIES" OR "THE COMPANY"), THE WORLD LEADER IN LISTERIA-BASED CANCER IMMUNOTHERAPIES, TODAY ANNOUNCED THAT IT HAS COMPLETED THE SUBMISSION ON CLINICAL AND BIOMARKER DATA FROM THE COMPANY'S PHASE 2B CLINICAL TRIAL OF OST-HER2 IN THE PREVENTION OF DELAY OF RECURRENT, FULLY RESECTED, PULMONARY METASTATIC OSTEOSARCOMA TO THE U.S. FOOD & DRUG ADMINISTRATION IN PREPARATION FOR THE COMPANY'S UPCOMING PRE-BLA MEETING, REPORTED FULL-YEAR 2025 FINANCIAL RESULTS FOR THE PERIOD ENDED DECEMBER 31, 2025 AND PROVIDED A BUSINESS UPDATE. THE COMPANY EXPECTS THE PRE-BLA MEETING TO OCCUR IN MAY 2026.

OS THERAPIES COMPLETES SUBMISSION OF BIOMARKER & CLINICAL DATA FOR U.S. FDA PRE-BLA MEETING, REPORTS FULL YEAR 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

FROM 1999 TOM FORD GUCCI TOL.L.BEAN BOAT AND TOTES, 10 NEW YORKERS SHARE WHAT'S MOVING FROM THEIR OWN CLOSETS TO THE MARKETPLACE, AND WHAT THEY'RE MAKING ROOM TO BUY NEXT SAN JOSE, CALIF., MARCH 26, 2026 /PRNEWSWIRE/ -- TODAY, EBAY UNVEILED THE NYC EDIT  AN ONLINE EDITORIAL GUIDE HIGHLIGHTING WHAT STYLE INSIDERS IN NEW YORK ARE BUYING AND SELLING ON EBAY, FEATURING CURATED SELECTIONS AND INSIGHTS FROM SOME OF THE CITY'S MOST IN-THE-KNOW TASTEMAKERS.

EBAY LAUNCHES 'THE NYC EDIT,' REVEALING WHAT NEW YORK'S MOST 'IN-THE-KNOW' TASTEMAKERS ARE SELLING AND BUYING

MILWAUKEE--(BUSINESS WIRE)-- #AMANDAKNOX--NEW YORK TIMES BESTSELLING AUTHOR, RENOWNED ACTIVIST, AND EXONEREE AMANDA KNOX ANNOUNCED AS NEOSTELLA'S 2026 NEOSUMMIT KEYNOTE SPEAKER.

The New York Times Company

NYT

Price

Financial Reports

No items found.

Press Releases

The New York Times Company

NYT.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

NYT